Cytokinetics Says Sanofi Acquiring Rights for Aficamten in Greater China

MT Newswires Live12-20 16:58

Cytokinetics (CYTK) said Friday that Sanofi (SNY) will acquire exclusive rights to develop and commercialize aficamten in Greater China to treat obstructive and non-obstructive hypertrophic cardiomyopathy.

The company said Corxel Pharmaceuticals acquired the rights to aficamten in Greater China from Cytokinetics in 2020. Sanofi is acquiring the rights from Corxel for an undisclosed amount.

Cytokinetics will be eligible to receive up to $150 million in development and commercial milestone payments from Sanofi, as well as royalties in the low-to-high teens on future sales in the region, the company said.

Cytokinetics is also eligible for further undisclosed payments tied to the agreement between Sanofi and Corxel, it said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492499391?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-20 16:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492499391","market":"sg","top_or_hot":-1,"title":"Cytokinetics Says Sanofi Acquiring Rights for Aficamten in Greater China","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CYTK\">Cytokinetics</a> (CYTK) said Friday that <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (SNY) will acquire exclusive rights to develop and commercialize aficamten in Greater China to treat obstructive and non-obstructive hypertrophic cardiomyopathy.</p><p>The company said Corxel Pharmaceuticals acquired the rights to aficamten in Greater China from Cytokinetics in 2020. Sanofi is acquiring the rights from Corxel for an undisclosed amount.</p><p>Cytokinetics will be eligible to receive up to $150 million in development and commercial milestone payments from Sanofi, as well as royalties in the low-to-high teens on future sales in the region, the company said.</p><p>Cytokinetics is also eligible for further undisclosed payments tied to the agreement between Sanofi and Corxel, it said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cytokinetics Says Sanofi Acquiring Rights for Aficamten in Greater China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytokinetics Says Sanofi Acquiring Rights for Aficamten in Greater China\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-20 16:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cytokinetics (CYTK) said Friday that Sanofi (SNY) will acquire exclusive rights to develop and commercialize aficamten in Greater China to treat obstructive and non-obstructive hypertrophic ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNYNF","symbol_name":"Sanofi","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2492499391","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492499391","pubTimestamp":1734685096,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cytokinetics (CYTK) said Friday that Sanofi (SNY) will acquire exclusive rights to develop and commercialize aficamten in Greater China to treat obstructive and non-obstructive hypertrophic cardiomyop","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNYNF":"Sanofi","BK4585":"ETF&股票定投概念","SNY":"赛诺菲安万特","BK4505":"高瓴资本持仓","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","CYTK":"Cytokinetics","BK4139":"生物科技","BK4588":"碎股","BK4007":"制药"},"translate_title":"Cytokinetics表示赛诺菲收购Aficamten在大中华区的权利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYTK":1,"SNYNF":1,"SNY":0.9},"content_text":"Cytokinetics (CYTK) said Friday that Sanofi (SNY) will acquire exclusive rights to develop and commercialize aficamten in Greater China to treat obstructive and non-obstructive hypertrophic cardiomyopathy.The company said Corxel Pharmaceuticals acquired the rights to aficamten in Greater China from Cytokinetics in 2020. Sanofi is acquiring the rights from Corxel for an undisclosed amount.Cytokinetics will be eligible to receive up to $150 million in development and commercial milestone payments from Sanofi, as well as royalties in the low-to-high teens on future sales in the region, the company said.Cytokinetics is also eligible for further undisclosed payments tied to the agreement between Sanofi and Corxel, it said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492499391"}